Key Highlights

  • Inovio shares are trading 14.62% lower at $0.7928 on Thursday, October 29, 2026.
  • The FDA target action date for INO-3107 is October 30, 2026.
  • Cash and investments totaled $36.7 million at June 30, 2026, not counting about $18.3 million raised in July.
  • The second-quarter net loss shrank to $6.0 million from $23.5 million, aided by a $13.9 million warrant gain.
  • Management expects cash to support operations into late Q1 2027.

Inovio Shares Slip: What Is Pressuring the Stock Before the FDA Date?

Inovio Pharmaceuticals (NASDAQ:INO) shares are trading 14.62% lower at $0.7928 on Thursday, October 29, 2026, from an implied prior close of about $0.9285 (calculated from the price and move). No dated company release accompanied the move, which arrives one day ahead of the FDA target action date for its main drug candidate.

Inovio develops DNA medicines. Its main program, INO-3107, is under FDA consideration for recurrent respiratory papillomatosis, a rare airway condition, and has received Orphan Drug and Breakthrough Therapy designations. The company applied under the accelerated approval pathway.

INO-3107 Application: Why Did the Accelerated Approval Question Matter?

On December 29, 2025, Inovio announced that the FDA had accepted its Biologics License Application with a standard review and a goal date of October 30, 2026. The agency said it did not plan an advisory committee. Shares dropped about 22% to $1.80 that day.

In its acceptance letter, the FDA stated a preliminary view that Inovio had not offered enough information to support eligibility for accelerated approval. The second-quarter update said the agency did not address that comment at an informal meeting, with feedback on confirmatory trial design due later.

The company said late-cycle review and all scheduled pre-licensure inspections were finished. Launch preparations were in progress, including a contract sales organization hiring medical science liaisons, as well as a logistics provider, specialty distributor, specialty pharmacy and patient hub.

Inovio Cash Position: How Far Does the Funding Stretch?

Cash, equivalents and short-term investments were $36.7 million at June 30, 2026, versus $58.5 million at December 31, 2025. An underwritten public offering completed in July brought net proceeds of about $18.3 million, which the June figure excludes.

Management expects cash to cover operations into late first quarter 2027, including a possible INO-3107 launch, assuming about $18 million of net cash burn in the third quarter and no new capital raises.

Second-quarter operating expenses were $18.6 million compared with $23.1 million, with R&D at $10.8 million and G&A at $7.8 million. The net loss was $6.0 million, or $0.07 per share, against $23.5 million, or $0.61, as a $13.9 million non-cash gain on warrant liabilities offset spending.

Inovio Equity and Pipeline: What Else Sits on the Table?

At June 30, total assets were $49.4 million and liabilities were $45.0 million, leaving stockholders' equity of $4.4 million versus $24.1 million at the end of 2025. Warrant liabilities stood at $25.0 million and the accumulated deficit at $1.84 billion. Weighted average shares were 81.6 million in the second quarter, compared with 38.8 million a year earlier.

Partner ApolloBio announced positive Phase 3 topline results in May 2026 for VGX-3100 in cervical dysplasia and plans to back a regulatory filing in China. Inovio is also advancing preclinical DNA-encoded protein programs and is talking with potential partners.

What to Watch Next: What Will the October 30 FDA Action Deliver?

The FDA target action date for INO-3107 is Friday, October 30, 2026. Next markers are the outcome, any stated route to approval and confirmatory trial requirements, plus the company's third-quarter cash position and financing needs.